ClinicalTrials.gg
CompletedNCT05064345Updated Sep 14, 2022

A Study to Evaluate HB0034 in Healthy Adult Participants

A Phase 1 interventional study of HB0034 and Placebo in Healthy, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose.

Read the detailed description

This is a first-in-human (FIH) study of HB0034 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd. is the lead sponsor of 19 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects age ≥ 18 and ≤ 55 years.
  • (BMI) ≥ 17.5 and ≤ 32 kg/m².
  • Normal , blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not .
  • Signed and dated written prior to admission to the study in accordance with GCP and local legislation.

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.
  • Current or history of .
  • Family history of premature Coronary Heart Disease (CHD)
  • History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
  • Pregnant or Breasting feeding subject. Women with a positive pregnancy test (HCG).
  • Further exclusions criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    HB0034 dose group 1

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 2

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 3

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 4

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 5

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 6

    HB0034 single dose

    Drug: HB0034

  • Active comparator
    HB0034 dose group 7

    HB0034 single dose

    Drug: HB0034

  • Placebo comparator
    Matching placebo for each dose group

    placebo, single dose

    Drug: Placebo

Interventions

  • DrugHB0034

    Recombinant Humanized Anti-IL-36R Monoclonal antibody

    Also known as: no other invention names

  • DrugPlacebo

    Palcebo

    Also known as: no other invention names

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with drug related adverse events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational drug

    Time frame: up to 2000 hours

Secondary outcomes

  1. Cmax

    The maximum measured concentration of the analysis in plasma

    Time frame: up to 2000 hours

Other outcomes

  1. AUC0-infinity

    The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity

    Time frame: up to 2000 hours

07

Study locations

1 site
  • New zealand Clinical Research
    Auckland, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Sep 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 1, 2021
StartActual
Dec 3, 2021
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05064345
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Dec 3, 2021
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Last update
Sep 14, 2022

Study contacts

Christian Schwabe
principal investigator · NZCR OpCo limited AKL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0034

Start the discussion